{"title":"durvalumab相关硬化性胆管炎的胆管造影作为免疫介导的不良事件。","authors":"Naosuke Kuraoka, Tetsuro Ujihara, Shun Sakai","doi":"10.1002/jhbp.12119","DOIUrl":null,"url":null,"abstract":"<p>Immune checkpoint inhibitor-related sclerosing cholangitis is most commonly associated with PD-1 or PD-L1 inhibitors. Kuraoka and colleagues report a novel case of cholangitis as an immune-mediated adverse event caused by durvalumab, with findings suggestive of the diagnosis observed on a cholangiogram obtained by endoscopic retrograde cholangiography.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":"32 6","pages":"e26-e27"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cholangiogram of durvalumab-related sclerosing cholangitis as immune-mediated adverse event\",\"authors\":\"Naosuke Kuraoka, Tetsuro Ujihara, Shun Sakai\",\"doi\":\"10.1002/jhbp.12119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Immune checkpoint inhibitor-related sclerosing cholangitis is most commonly associated with PD-1 or PD-L1 inhibitors. Kuraoka and colleagues report a novel case of cholangitis as an immune-mediated adverse event caused by durvalumab, with findings suggestive of the diagnosis observed on a cholangiogram obtained by endoscopic retrograde cholangiography.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":16056,\"journal\":{\"name\":\"Journal of Hepato‐Biliary‐Pancreatic Sciences\",\"volume\":\"32 6\",\"pages\":\"e26-e27\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepato‐Biliary‐Pancreatic Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12119\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12119","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Cholangiogram of durvalumab-related sclerosing cholangitis as immune-mediated adverse event
Immune checkpoint inhibitor-related sclerosing cholangitis is most commonly associated with PD-1 or PD-L1 inhibitors. Kuraoka and colleagues report a novel case of cholangitis as an immune-mediated adverse event caused by durvalumab, with findings suggestive of the diagnosis observed on a cholangiogram obtained by endoscopic retrograde cholangiography.
期刊介绍：
The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
